Fennec PharmaceuticalsFENC
FENC
About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Employees: 32
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
36% more capital invested
Capital invested by funds: $74.7M [Q3] → $101M (+$26.8M) [Q4]
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
3.93% more ownership
Funds ownership: 54.57% [Q3] → 58.51% (+3.93%) [Q4]
2% more funds holding
Funds holding: 63 [Q3] → 64 (+1) [Q4]
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
131%
upside
Avg. target
$13
131%
upside
High target
$13
131%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 36% 1-year accuracy 117 / 329 met price target | 131%upside $13 | Buy Reiterated | 11 Mar 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
2 weeks ago
Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Seeking Alpha
1 month ago
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call.
Negative
Zacks Investment Research
1 month ago
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~
Neutral
GlobeNewsWire
1 month ago
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2024 financial results before the opening of the U.S. financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Neutral
GlobeNewsWire
2 months ago
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to
Neutral
Zacks Investment Research
3 months ago
Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock?
Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately.
Neutral
GlobeNewsWire
4 months ago
Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~
Neutral
GlobeNewsWire
4 months ago
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company's approximately $32 million outstanding convertible debt facility with Petrichor Healthcare Capital Management (“Petrichor”).
Neutral
GlobeNewsWire
4 months ago
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET.
Charts implemented using Lightweight Charts™